Hansa Biopharma’s Strong Q4: SEK 50m Revenue

Hansa Biopharma Reports Strong Q4 Revenue Growth and Expansion into New Markets

Hansa Biopharma, a leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, has announced impressive results for the fourth quarter of 2023. The company expects to report total revenue of SEK 50 million, with SEK 43 million stemming from sales of its product Idefirix®. This surge in revenue is primarily due to market growth in the U.K., Germany, and Spain. This achievement reflects the success and increasing demand for Hansa Biopharma’s innovative therapeutic solutions.